<DOC>
	<DOCNO>NCT01430689</DOCNO>
	<brief_summary>The Center Vaccine Development - Mali interested learn vaccinate pregnant woman influenza protect infant disease . The investigator know influenza infection , `` flu '' , affect pregnant woman infant Mali . The illness know flu cause germ ( virus ) pass easily among people . The flu cause symptom fever , cough , sore throat , runny nose , body ache . Certain group people , pregnant woman infant , risk severe disease get flu . Vaccination influenza routinely available pregnant woman Mali although recommend . Women wish participate 5 visit clinic weekly visit home follow health woman infant bear . The investigator also ask permission make weekly visit child 5 year age follow health relates influenza infection . A substudy add December 2014 test subset nasal/oropharyngeal sample collect pregnant woman infant RSV pertussis describe epidemiologyof infection population . Additional testing store serum sample individual attempt identify protective titer antibody could protect infant infection .</brief_summary>
	<brief_title>Maternal Flu Vaccine Trial Bamako , Mali</brief_title>
	<detailed_description>This prospective , randomize , control observer-blind trial measure efficacy , safety immunogenicity TIV safety immunogenicity MCV pregnant woman infant 6 month age . Women recruit 3rd trimester pregnancy vaccinate either TIV MCV . Safety assessment woman complete 30 minute 1 week vaccination , delivery 3 6 month delivery . Safety assessment infant complete birth 3 6 month age . Immunogenicity assessment include blood sample woman immediately prior vaccination , 4 week post-vaccination , delivery 3 6 month delivery ; infant cord blood collect birth peripheral blood collection 3 6 month age . Visits ascertain cost related ILI LCI also conduct . The majority activity conduct trial related efficacy assessment continue newborn infant 6 month age . We conduct case detection LCI via weekly household visit . In addition , hospital-based surveillance meningococcal disease conduct measure efficacy MCV .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Women third trim pregnancy ( ≥ 28 week gestational age base upon last menstrual period , ultrasound uterine height ) . 2 . Subject able understand comply plan study procedure . 3 . Subject provide write informed consent prior initiation study procedure . 4 . Subject intend reside study area newborn infant 6 month age . 1 . Member household already woman participate participate study 2 . History severe reaction follow previous immunization influenza meningococcal vaccine 3 . History GuillainBarré Syndrome 4 . Known allergy hypersensitivity egg , egg protein , latex , diphtheria toxoid , component Vaxigrip Menactra 5 . Known chronic medical condition judgment investigator could compromise evaluation study vaccine put subject risk 6 . Known active infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C 7 . Any following complication ongoing pregnancy : preterm labor ( cervical change ) , placental abruption , premature rupture membrane , know major congenital anomaly , preeclampsia . 8 . Acute illness and/or oral temperature great equal 37.8 degree C , within 72 hour vaccination ( This may result temporary delay vaccination ) 9 . Receipt vaccine , exclude tetanus toxoid , within 2 week ( inactivated vaccine ) 4 week ( live vaccine meningococcal A conjugate vaccine ( MenAfriVac ) ) prior vaccination study 10 . Woman intend travel study area 40 day delivery 11 . Receipt immunoglobulins and/or blood product within 30 day prior administration study vaccine 12 . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying agent within 90 day prior administration study vaccine ( include systemic corticosteroid , e.g . prednisone equivalent &gt; 0.5 mg/kg/day ; topical inhale steroid allow ) 13 . Any condition opinion investigator might compromise wellbeing participant compliance study procedure interfere evaluation study vaccine</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Neonates</keyword>
</DOC>